Risk-Based, Response-Adapted, Phase II Open-Label Trial of Nivolumab + Brentuximab Vedotin N + BV For Children, Adolescents, and Young Adults with Relapsed/Refractory R/R CD30 + Classic Hodgkin Lymphoma Chl After Failure of First-Line Therapy, Followed By Brentuximab + Bendamustine BV + B for Participants with a Suboptimal Response

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT02927769

Study #:
CMH - AHOD1721

Start Date:
Sep 18, 2017

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02927769

View Complete Trial Details & Eligibility at ClinicalTrials.gov